Triazine derivatives as differentiation catalysts

A method of inducing differentiation of mammalian cells into cardiomyocyte-like cells by contacting the mammalian cell with a triazine compound of formula (I), wherein X is independently -NR4-or -O-, R4 is hydrogen or C1-6-alkyl; R1 is hydroxy, C1-6-alkyl, C1-6-alkoxy, carboxy, C1-6-alkoxycarbonyl,...

Full description

Saved in:
Bibliographic Details
Main Authors Mihovilovic Marko, Mike Agnes, Linder Thomas, Schnuerch Michael, Koenig Xaver, Hilber Karlheinz
Format Patent
LanguageEnglish
Published 04.04.2017
Subjects
BEER
BIOCHEMISTRY
CHEMISTRY
COMPOSITIONS THEREOF
CULTURE MEDIA
ENZYMOLOGY
HETEROCYCLIC COMPOUNDS
METALLURGY
MICROBIOLOGY
MICROORGANISMS OR ENZYMES
MUTATION OR GENETIC ENGINEERING
ORGANIC CHEMISTRY
PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS
SPIRITS
VINEGAR
WINE
Online AccessGet full text

Cover

More Information
Summary:A method of inducing differentiation of mammalian cells into cardiomyocyte-like cells by contacting the mammalian cell with a triazine compound of formula (I), wherein X is independently -NR4-or -O-, R4 is hydrogen or C1-6-alkyl; R1 is hydroxy, C1-6-alkyl, C1-6-alkoxy, carboxy, C1-6-alkoxycarbonyl, halo, cyano, nitro, formyl, amino, C1-6-alkylamino, or di-C1-6-alkylamino, the C1-6-alkyl or -alkoxy residue being optionally substituted with one or more R5 substituents selected from hydroxy, halo, cyano, and nitro; n is 0 to 5; R2 is hydrogen, aryl, heteroaryl, or C1-6-alkyl, the aryl or heteroaryl residue being optionally substituted with one or more R1 substituents, and where the C1-6-alkyl is optionally further substituted with one or more R5 substituents; and R3 is selected from hydrogen, halo, NR4R7, OR7, SR7, and R7, where the same options apply for R7 as for R2; with the proviso that the compound of formula (I) is not 3-[(4,6-diphenoxy-1,3,5-triazin-2-yl)amino]benzoic acid.
Bibliography:Application Number: US201214346328